{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202314","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.829021+00:00","generated_at":"2026-06-12T08:38:52.276631+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Prelude posts Q2 net loss $30.4M; cash $255M funds operations into 2026","bullets":["Net loss of $30.4M ($0.54/share) vs $27.4M ($0.58/share) in Q2 2022.","R&D expense rose to $25.0M from $21.3M YoY; G&A fell to $7.4M from $8.2M.","Cash, equivalents and marketable securities $255.0M; completed public offering raising $113M gross.","Pipeline milestones: CDK9 (PRT2527) confirmation dose target Q1 2024; SMARCA2 degrader IND early 2024.","Management expects cash runway into 2026; four lead programs on track for data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202314","json":"https://secwatch.observer/filing/0001193125-23-202314.json","markdown":"https://secwatch.observer/filing/0001193125-23-202314.md","text":"https://secwatch.observer/filing/0001193125-23-202314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/0001193125-23-202314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/d870924d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:38:52.276631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}